| First Author | Vonderheide RH | Year | 2018 |
| Journal | Cancer Cell | Volume | 33 |
| Issue | 4 | Pages | 563-569 |
| PubMed ID | 29634944 | Mgi Jnum | J:260704 |
| Mgi Id | MGI:6150963 | Doi | 10.1016/j.ccell.2018.03.008 |
| Citation | Vonderheide RH (2018) The Immune Revolution: A Case for Priming, Not Checkpoint. Cancer Cell 33(4):563-569 |
| abstractText | Most tumors are unresponsive to immune checkpoint blockade, especially if deep immunosuppression in the tumor develops prior to and prevents T cell immunosurveillance. Failed or frustrated T cell priming often needs repair before successful sensitization to PD-1/PD-L1 blockade. CD40 activation plays a critical role in generating T cell immunity, by activating dendritic cells, and converting cold tumors to hot. In preclinical studies, agonistic CD40 antibodies demonstrate T cell-dependent anti-tumor activity, especially in combination with chemotherapy, checkpoint inhibitory antibodies, and other immune modulators. With the advent of multiple CD40 agonists with acceptable single-agent toxicity, clinical evaluation of CD40 combinations has accelerated. |
